The changing face of hypophosphatemic disorders in the FGF-23 era.

Janet Y. Lee, Erik Imel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In the past decade, research in genetic disorders of hypophosphatemia has significantly expanded our understanding of phosphate metabolism. X-linked hypophosphatemia (XLH) is the most common inherited form of rickets due to renal phosphate wasting. Recent understanding of the mechanisms of disease and role of fibroblast growth factor 23 (FGF-23) in XLH and other hypophosphatemic disorders have opened new potential therapeutic avenues. We will discuss the current standard of treatment for XLH as well as promising future directions under study.

Original languageEnglish (US)
Pages (from-to)367-379
Number of pages13
JournalPediatric Endocrinology Reviews
Volume10 Suppl 2
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Familial Hypophosphatemic Rickets
Phosphates
Hypophosphatemia
Rickets
Inborn Genetic Diseases
Kidney
Research
fibroblast growth factor 23
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

The changing face of hypophosphatemic disorders in the FGF-23 era. / Lee, Janet Y.; Imel, Erik.

In: Pediatric Endocrinology Reviews, Vol. 10 Suppl 2, 06.2013, p. 367-379.

Research output: Contribution to journalArticle

@article{cdb0010c81b24ff1b28a19b1fb9deba1,
title = "The changing face of hypophosphatemic disorders in the FGF-23 era.",
abstract = "In the past decade, research in genetic disorders of hypophosphatemia has significantly expanded our understanding of phosphate metabolism. X-linked hypophosphatemia (XLH) is the most common inherited form of rickets due to renal phosphate wasting. Recent understanding of the mechanisms of disease and role of fibroblast growth factor 23 (FGF-23) in XLH and other hypophosphatemic disorders have opened new potential therapeutic avenues. We will discuss the current standard of treatment for XLH as well as promising future directions under study.",
author = "Lee, {Janet Y.} and Erik Imel",
year = "2013",
month = "6",
language = "English (US)",
volume = "10 Suppl 2",
pages = "367--379",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",

}

TY - JOUR

T1 - The changing face of hypophosphatemic disorders in the FGF-23 era.

AU - Lee, Janet Y.

AU - Imel, Erik

PY - 2013/6

Y1 - 2013/6

N2 - In the past decade, research in genetic disorders of hypophosphatemia has significantly expanded our understanding of phosphate metabolism. X-linked hypophosphatemia (XLH) is the most common inherited form of rickets due to renal phosphate wasting. Recent understanding of the mechanisms of disease and role of fibroblast growth factor 23 (FGF-23) in XLH and other hypophosphatemic disorders have opened new potential therapeutic avenues. We will discuss the current standard of treatment for XLH as well as promising future directions under study.

AB - In the past decade, research in genetic disorders of hypophosphatemia has significantly expanded our understanding of phosphate metabolism. X-linked hypophosphatemia (XLH) is the most common inherited form of rickets due to renal phosphate wasting. Recent understanding of the mechanisms of disease and role of fibroblast growth factor 23 (FGF-23) in XLH and other hypophosphatemic disorders have opened new potential therapeutic avenues. We will discuss the current standard of treatment for XLH as well as promising future directions under study.

UR - http://www.scopus.com/inward/record.url?scp=84881360794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881360794&partnerID=8YFLogxK

M3 - Article

C2 - 23858620

AN - SCOPUS:84881360794

VL - 10 Suppl 2

SP - 367

EP - 379

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

ER -